Phase 3 RCT in 1328 participants in India and South Africa: one dose of MenACYW-TT was non-inferior to MenACYW-DT for seroprotection against all four serogroups in those aged 2–17, with comparable reactions and no vaccine-related serious AEs.
RCTn = 1,328
Bavdekar et al. A phase III randomized study: Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine in healthy adults, adolescents, and children in India and healthy adolescents and children in South Africa